Document Type
Article
Publication Date
9-17-2025
Identifier
DOI: 10.1093/neuonc/noaf092; PMCID: PMC12448823
Abstract
BACKGROUND: Sonic hedgehog (SHH) medulloblastoma is the most common molecular group of infant and early childhood medulloblastoma (iMB) and has no standard of care at relapse. This work aimed to evaluate the post-relapse survival (PRS) and explore prognostic factors of patients with nodular desmoplastic (ND) and/or SHH iMB.
METHODS: This international retrospective study included 147 subjects diagnosed with relapsed ND/SHH iMB between 1995 and 2017, < 6 years old at original diagnosis, and treated without initial craniospinal irradiation (CSI). Univariable and multivariable Cox models with propensity score analyses were used to assess PRS for those in the curative intent cohort.
RESULTS: The 3-year PRS was 61.6% (95% confidence interval [CI], 52.2-69.6). The median age at relapse was 3.4 years (interquartile range [IQR], 2.6-4.1). Those with local relapse (40.8%) more often received salvage treatment with surgery (P < .001), low-dose CSI (≤24 Gy; P < .001), or focal radiotherapy (P = .008). Patients not receiving CSI (40.5%) more often received salvage marrow-ablative chemotherapy (HDC + AuHCR [P < .001]). On multivariable analysis, CSI was associated with improved survival (hazard ratio [HR] 0.33 [95% CI, 0.13-0.86], P = .04). Salvage HDC + AuHCR, while clinically important, did not reach statistical significance (HR 0.24 [95% CI, 0.0054-1.025], P = .065).
CONCLUSIONS: Survival of patients with relapsed SHH iMB is not satisfactory and relies on treatments associated with toxicities including CSI and/or HDC + AuHCR. Cure at initial diagnosis to avoid relapse is crucial. For patients with localized relapse undergoing resection, alternative salvage regimens that avoid high-dose CSI (>24 Gy) can be considered.
Journal Title
Neuro Oncol
Volume
27
Issue
8
First Page
2158
Last Page
2169
MeSH Keywords
Humans; Medulloblastoma; Male; Female; Salvage Therapy; Child, Preschool; Retrospective Studies; Neoplasm Recurrence, Local; Cerebellar Neoplasms; Hedgehog Proteins; Infant; Prognosis; Survival Rate; Follow-Up Studies; Combined Modality Therapy; Child
PubMed ID
40186336
Keywords
SHH; infant and early childhood; medulloblastoma; relapse
Recommended Citation
Erker C, Mynarek M, Simbozel M, et al. Salvage therapies for first relapse of SHH medulloblastoma in early childhood. Neuro Oncol. 2025;27(8):2158-2169. doi:10.1093/neuonc/noaf092


Comments
Grants and funding
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Publisher's Link: https://academic.oup.com/neuro-oncology/article/27/8/2158/8106615?login=false